USFDA21 Aug 2024, 04:58 pm
Marksans Pharma's Subsidiary, Relonchem, Secures Marketing Authorization from UKMHRA for Fluoxetine Capsules
AI Summary
Marksans Pharma Limited, a Mumbai-based pharmaceutical company, announces that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the United Kingdom Medicines and Healthcare products Regulatory Agency (UKMHRA) for Fluoxetine 10mg, 30mg, and 60mg capsules. This authorization marks a significant milestone for Marksans Pharma, expanding its global reach and reinforcing its commitment to quality and innovation in the pharmaceutical industry.
Key Highlights
- Marksans Pharma's subsidiary, Relonchem Limited, receives Marketing Authorization from UKMHRA for Fluoxetine capsules in three dosages.
- The company's manufacturing facilities are approved by several leading regulatory agencies, including USFDA, UKMHRA, and Australian TGA.
- Marksans Pharma's product portfolio covers major therapeutic segments, such as CVS, CNS, Anti-diabetic, Pain Management, Upper respiratory, and Gastroenterological.
- The company is marketing its products globally, reinforcing its commitment to quality and innovation in the pharmaceutical industry.
- The announcement signifies a significant milestone for Marksans Pharma, expanding its global reach and influence.